2.7
Impact Factor
4.5
CiteScore
20 days
Time to First Decision

Antibodies, Volume 4, Issue 1

2015 March - 5 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (5)

Select all

Review

74 Citations

24,441 Views

23 Pages

Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy

Roman Fischer,
Roland E. Kontermann and
Olaf Maier

Antibodies2015, 4(1), 48-70;https://doi.org/10.3390/antib4010048

6 March 2015

Deregulation of the tumor necrosis factor (TNF) plays an important role in the initiation and perpetuation of chronic inflammation and has been implicated in the development of various autoimmune diseases. Accordingly, TNF-inhibitors are successfully...

Full Article

Article

5 Citations

9,909 Views

14 Pages

TNFR1 and TNFR2 Expression and Induction on Human Treg Cells from Type 1 Diabetic Subjects

Melanie Heinrich,
Douglas Burger,
Limei Wang,
Georges Tahhan,
Peter Reinhold,
Menghan Zhao,
Elise Hsu,
Sarah Warden,
Danielle Baum and
Denise L Faustman

Antibodies2015, 4(1), 34-47;https://doi.org/10.3390/antib4010034

3 March 2015

Several autoimmune diseases are marked by a deficiency of soluble tumor necrosis factor (TNF). The TNF deficiency is caused in at least one autoimmune disease, multiple sclerosis, by an overabundance of TNF receptor 1 (TNFR1). Excess TNFR1 binds and...

Full Article

Review

59 Citations

24,870 Views

22 Pages

Cell-Free Synthesis Meets Antibody Production: A Review

Marlitt Stech and
Stefan Kubick

Antibodies2015, 4(1), 12-33;https://doi.org/10.3390/antib4010012

26 January 2015

Engineered antibodies are key players in therapy, diagnostics and research. In addition to full size immunoglobulin gamma (IgG) molecules, smaller formats of recombinant antibodies, such as single-chain variable fragments (scFv) and antigen binding f...

Full Article

Editorial

4,096 Views

1 Page

Acknowledgement to Reviewers of Antibodies in 2014

Antibodies Editorial Office

Antibodies2015, 4(1), 11;https://doi.org/10.3390/antib4010011

9 January 2015

The editors of Antibodies would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2014:[...]

Full Article

Communication

6,095 Views

10 Pages

Both Tumor Necrosis Factor Receptor Signaling Pathways Contribute to Mortality but not to Splenomegaly in Generalized Lymphoproliferative Disorder

Florian Wiede,
Alicia Roomberg,
Jocelyn Darby,
Rene Gollan and
Heinrich Körner

Antibodies2015, 4(1), 1-10;https://doi.org/10.3390/antib4010001

24 December 2014

The phenotypical consequences of a combined deficiency of the Fas-Fas Ligand (FasL) and one or both Tumor Necrosis Factor (TNF) signaling pathways were investigated. Mice, which expressed a non-functional FasL suffered from a pathological accumulatio...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Antibodies - ISSN 2073-4468

Imprint

Download Flyer